Clinical trials: Metastasis Colorectal Cancer
Colorectal Cancer
Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer
The FC-7 study is designed as an open label, single arm, Phase I/II dose-escalation study evaluating the combination of neratinib and cetuximab in patients with metastatic colorectal cancer primary tumor that is "quadruple…
- Trial name
- NCT01960023
- Testing
- Cetuximab, Neratinib
- Where
- 12 sites in United States
- Sponsor
- NSABP Foundation Inc
Colorectal Cancer Metastatic
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
Microdevices have been used to ascertain in vivo drug response, which can lead to improved cancer treatment delivery; however, they have not been evaluated for liver tumors.
- Trial name
- NCT07193862
- Testing
- Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Northwell Health
Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
The aim of this multicenter randomized phase II trial is to determine the efficacy of sorafenib and irinotecan combination versus irinotecan monotherapy or versus sorafenib monotherapy in metastatic colorectal cancer patients…
- Trial name
- NEXIRI2 (NCT01715441)
- Testing
- Sorafenib and irinotecan combination, Sorafenib monotherapy, Irinotecan monotherapy
- Where
- 9 sites in France
- Volunteers
- 173 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Recurrent Colon Cancer, Recurrent Rectal Cancer
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer
This phase I/II trial is studying the side effects and best dose of sorafenib when given together with cetuximab and irinotecan and to see how well they work in treating patients with advanced or metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer
- Trial name
- NCT00134069
- Testing
- sorafenib tosylate, cetuximab, irinotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Curative Proton Beam Therapy for Patients With Liver Metastasis of Colorectal Cancer
Proton alone therapy is performed -> 5 times a week, 7200 cGy / 15 fractions for 3 weeks total
- Trial name
- NCT03577665
- Testing
- curative proton therapy
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- National Cancer Center, Korea
Metastatic Colorectal Cancer
Study of Circulating Markers in Serum of Patients Treated for Metastatic Colorectal Cancer
The primary purpose of the study is to confirm the results of previous study about the usefulness of the serum Carcinoembryonic antigen (CEA) kinetic for chemotherapy monitoring in patients with unresectable metastasis of…
- Trial name
- Coca-Colon (NCT01212510)
- Testing
- Blood sampling
- Where
- 4 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Rouen
KRAS Gene, Colorectal Cancer
To Identify KRAS Gene and Safe Margin in Association With Outcome in Colorectal Liver Metastases Following Ultrasound-guided Radiofrequency Ablation
To investigate the clinical effect of radiofrequency ablation on colorectal cancer liver metastases with different KRAS gene status
- Conditions
- KRAS Gene, Colorectal Cancer, Liver Metastasis, Safe Margin
- Trial name
- NCT04417010
- Testing
- Radiofrequency ablation
- Volunteers
- 163 people
- Sponsor
- Peking University Cancer Hospital & Institute
Liver Metastases, Colorectal Cancer
EXtended CriteriA Treatment for LIver Metastases and Heavy Tumour BURden
Patients with multiple colorectal liver metastases that progress on 1st line chemotherapy have a very dismal prognosis, and their options are few.
- Trial name
- EXCALIBUR3 (NCT04840186)
- Testing
- Liver-resection or ablation, 2nd line chemotherapy
- Where
- Norway
- Volunteers
- 62 people
- Sponsor
- Oslo University Hospital
Metastatic Colorectal Cancer
Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer
The objective is to compare the efficacy and safety of masitinib in combination with FOLFIRI ( irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients.
- Trial name
- NCT02605044
- Testing
- Masitinib (AB1010), FOLFIRI
- Where
- 3 sites in France, Singapore and 1 more
- Volunteers
- 123 people
- Sponsor
- AB Science
Colorectal Neoplasms
The Role of the Tumor Molecular Profile (CMS), UGT1A1 Genotype and Beta-glucuronidase Activity of the Intestinal Microbiota for Treatment Efficiency, Toxicity, Survival and Quality of Life in Patients With Metastatic or Unresectable Colorectal Cancer During Irinotecan-based Systemic Treatment
Irinotecan-based systemic therapy is a treatment option for metastatic or unresectable colorectal cancer. However, this therapy has two major disadvantages, namely, an unpredictable response to the treatment and severe side…
- Trial name
- OPTIMA (NCT05655780)
- Where
- Netherlands
- Volunteers
- 104 people
- Sponsor
- Maastricht University Medical Center
Metastatic Malignant Neoplasm
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors.
- Trial name
- NCT05958199
- Testing
- NPX267
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- NextPoint Therapeutics, Inc.
Refractory Metastatic Colorectal Cancer
Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
This study is designed as an international, open-label, controlled two-arm, randomized phase III comparison study evaluating the efficacy and safety of trifluridine/tipiracil in combination with bevacizumab versus…
- Trial name
- SUNLIGHT (NCT04737187)
- Testing
- Trifluridine/Tipiracil, Bevacizumab
- Where
- 99 sites in United States, Austria and 12 more
- Volunteers
- 492 people
- Sponsor
- Taiho Oncology, Inc.
First Line WT KRAS mCRC
PREMIUM, Observational Study
PREMIUM is an observational pharmaco-epidemiologic, transversal, multi-centric, prospective cohort study and with independent investigators.
- Trial name
- NCT01756625
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Dr.Laurent Mineur
Metastatic Colorectal Cancer
FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer
The purpose of the study is to evaluate if the exposure to all the three active cytotoxic agents (FOLFOXIRI regimen) is superior in terms of progression-free survival to conventional chemotherapy with the FOLFOX regimen as…
- Trial name
- NCT02128425
- Testing
- FOLFOXIRI, FOLFOX
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer, Pancreatic Cancer
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
Phase 1b study evaluating the efficacy and immune response to a synthetic long peptide mutant KRAS vaccine (SPL mKRASvax) combined with Balstilimab and Botensilimab for unresectable or metastatic mismatch repair-proficient…
- Trial name
- NCT06411691
- Testing
- KRAS Vaccine with Poly-ICLC adjuvant, Balstilimab, Botensilimab
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655)
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping the cells from dividing.
- Trial name
- NCT00023868
- Testing
- FOLFIRI regimen, cisplatin, doxorubicin hydrochloride
- Where
- 9 sites in United States
- Sponsor
- American College of Radiology Imaging Network
CRC (Colorectal Cancer)
PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
PM8002 (BNT327) is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II trial to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in first line MSS or MSI-L/pMMR metastatic colorectal…
- Trial name
- NCT07133750
- Testing
- PM8002, Chemotherapy Regimen 1, Chemotherapy Regimen 2
- Where
- 11 sites in China
- Volunteers
- 100 people
- Sponsor
- Biotheus Inc.
Colorectal Cancer
Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
- Trial name
- NCT00049101
- Testing
- erlotinib hydrochloride, fluorouracil, leucovorin calcium
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colon Cancer, Rectal Cancer
Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases
Colorectal carcinoma with liver metastasis is one of the major problems bothering physicians worldwide. Bevacizumab combined with chemotherapy is the standard treatment recommended by several guidelines.
- Conditions
- Colon Cancer, Rectal Cancer, Liver Metastases
- Trial name
- ROBOT (NCT04213222)
- Testing
- Bevacizumab
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University People's Hospital
Colorectal Carcinoma
XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer
The first phase II trial with cetuximab and FOLFOX, as 1st line therapy for MCRC, presented at ASCO 2004, showed a 81% response rate, with no unexpected toxicities for the combination.
- Trial name
- NCT00215722
- Testing
- Cetuximab
- Where
- 10 sites in Portugal
- Volunteers
- 45 people
- Sponsor
- Grupo de Investigacao do Cancro Digestivo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.